Last reviewed · How we verify

NCT04898452: Hosp@Home

Intravenous Antibiotic Treatment at Home

Recruiting now Last updated 22 June 2025
What this trial tests

trial testing A new model of interaction across health services with use of welfare technology and telemedicine in Infection in 50 participants. Currently enrolling.

Timeline
2 July 2020
Primary endpoint
31 December 2025
31 December 2026

Quick facts

Lead sponsorHelse Møre og Romsdal HF
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date2 July 2020
Primary completion31 December 2025
Estimated completion31 December 2026
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Helse Møre og Romsdal HF — full company profile →

Who can join

18 and older, any sex, with Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to develop and evaluate a new model for across services interaction with the use of welfare technology and telemedicine. The model includes innovative and new routines for the exchange of patient information, quality systems and procedures between the municipality and the hospital. This model will first be tested for use in intravenous antibiotic therapy. The results of the study will be used to further develop the service. In the larger context, it is desirable to provide knowledge that is transferable to other diagnostic groups, treatment methods and geographical areas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Infection

Currently open trials in the same condition.

Other Helse Møre og Romsdal HF trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04898452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing